|
Thyroid carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that activating mutation of BRAF gene could be a potentially useful marker of prognosis of patients with advanced thyroid cancers.
|
12970315 |
2003 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
|
12670889 |
2003 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway.
|
14508525 |
2003 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hypermethylation of the tumor suppressor gene RASSF1A and activating mutation of BRAF gene have been reported recently in thyroid cancers.
|
14996725 |
2004 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
|
15272920 |
2004 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Understanding the genetic alterations underlying the development of anaplastic thyroid carcinoma, such as mutational activation of BRAF, could help clarify its relationship with well-differentiated forms of thyroid carcinoma (ie follicular and papillary carcinoma) and could help select patients most likely to benefit from novel therapeutic strategies targeting BRAF.
|
15195111 |
2004 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to disclose the role of BRAF mutations in thyroid carcinoma development.
|
15126572 |
2004 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas.
|
15356020 |
2004 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the differences between the characteristics of childhood and adult PTCs, we analyzed both BRAF(T1796A) and RAS mutations in 31 Japanese and 48 post-Chernobyl Ukrainian thyroid carcinomas.
|
15356022 |
2004 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
|
15630448 |
2005 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data identify a relationship between the methylation-associated silencing of the tumor-suppressor gene SLC5A8 and the T1796A point mutation of the BRAF gene in the PTC-cf. subtype of thyroid carcinomas.
|
15687339 |
2005 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical evaluation of B-RAF-targeting drugs is undergoing and trials in thyroid cancer are planned.
|
16940797 |
2006 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea], a multikinase inhibitor able to inhibit RAF family kinases in a panel of six (V600E)BRAF-positive thyroid carcinoma cell lines and in nude mice bearing ARO cell xenografts.Statistical tests were two sided.
|
16533790 |
2006 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
|
16784975 |
2006 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Clinical evaluation of B-RAF-targeting drugs is undergoing and trials in thyroid cancer are planned.
|
16940797 |
2006 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers.
|
17054470 |
2006 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The BRAF mutation may influence the expression patterns of molecular markers that are related to the development and progression of thyroid cancer.
|
16772349 |
2006 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data unmask an epigenetically controlled FGFR2 signal that imposes precisely on the intragenically modified BRAF/MAPK pathway to modulate thyroid cancer behavior.
|
17545628 |
2007 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
|
17911174 |
2007 |
|
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also compared the effect of a B-Raf small inhibitory RNA construct and the B-Raf kinase inhibitor AAL881 on both B-Raf wild-type and mutant thyroid carcinoma cell lines.
|
17363500 |
2007 |
|
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In summary, our results indicate that constitutive signalling of the MAP kinase cascade contributes to the development of thyroid cancer promoted by activated RAS and BRAF oncogenes and that this occurs, at least in part, by compromising the inhibitory function of p27.
|
18032931 |
2007 |
|
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
|
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |